DrugPatentWatch Database Preview

Details for Patent: 8,097,653

« Back to Dashboard

Which drugs does patent 8,097,653 protect, and when does it expire?

Patent 8,097,653 protects AMITIZA and is included in one NDA.

This patent has twenty-two patent family members in fourteen countries.

Summary for Patent: 8,097,653

Title:	Dosage unit comprising a prostaglandin analog for treating constipation
Abstract:	A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention comprises a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects.
Inventor(s):	Ueno; Ryuji (Montgomery, MD), Patchen; Myra L. (Fairfax, VA)
Assignee:	Sucampo AG (Zug, CH)
Application Number:	10/293,516
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,097,653
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,097,653

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006		RX	Yes	Yes

International Family Members for US Patent 8,097,653

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	037524
Argentina	098997
Austria	522218
Brazil	0214075
Canada	2464420